RESUMEN
The method of cell-associated antibiotic therapy consists of extracorporal exposure of the autoblood formed elements to antibiotic solution followed by their reinfusion. Pharmacokinetics of erythromycin after its intravenous and cell-associated administration in patients with community-acquired pneumonia and the clinical efficacy of the method were evaluated. HPLC of the erythromycin pharmacokinetic pattern in 20 patients showed that after the antibiotic target transport the pharmacokinetic model changed from one-compartment to two-compartment one and the antibiotic maximum concentration and elimination rate were lower vs. the intravenous administration. It was also shown that the clinical efficacies of the erythromycin intravenous administration and target transport did not significantly differ, whereas after the cell-associated transport of the antibiotic the therapeutic effect was observed earlier and the side effects were less frequent.
Asunto(s)
Antibacterianos/farmacocinética , Transfusión de Sangre Autóloga , Eritromicina/farmacocinética , Neumonía/metabolismo , Adulto , Antibacterianos/administración & dosificación , Antibacterianos/metabolismo , Células Sanguíneas/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Eritromicina/administración & dosificación , Eritromicina/metabolismo , Femenino , Humanos , Infusiones Intravenosas , Masculino , Neumonía/tratamiento farmacológicoRESUMEN
Under study were catalase activity and indicators of lipid peroxidation (LP) of donor blood exposed to different doses of UV irradiation. Doses lower than 630 J/m2 were found to activate catalase and to inhibit LP while doses higher than 630 J/m2 inhibited catalase activity and activated LP. The indicators of LP have confirmed that therapeutic doses of UV-irradiated blood were nontoxic. The most optimal therapeutic dose of irradiation (630 J/m2) was determined.